Javascript must be enabled to continue!
Epidemiological Profile of Patients with Spondylodiscitis Treated at the Hospital Da Restauracao
View through CrossRef
Introduction: Spondylodiscitis is a global term that includes vertebral osteomyelitis, spondylitis and discitis, representing approximately 3 to 5% of all cases
of osteomyelitis. It occurs in around 0.5 to 2.5 cases per 100,000 inhabitants/year, with men being more affected. It has a bimodal peak incidence, the first peak
up to 20 years and the second between 50 and 70 years. Most cases have an indication for non-surgical treatment, so surgery is reserved for specific cases.
Objective: To analyze the epidemiology of the population affected by spondylodiscitis and assess the response to surgical treatment.
Methods: We conducted a prospective cohort study in a tertiary center in Pernambuco, Recife, Brazil, investigating spondylodiscitis in all patients with back
pain without a history of trauma or neurological deficit without a diagnosis of degenerative spine disease. The diagnosis of spondylodiscitis was confirmed
in all cases with magnetic resonance imaging. The study period was two years.
Results: During the study period, we diagnosed 31 patients with spondylodiscitis, 58% were male, the mean age was 64.9 years, the main comorbidities
were systemic arterial hypertension, dialysis renal failure and diabetes, previous non-neurological surgeries (Caesarean births, permanent vascular catheter
for dialysis, cardiac surgery on the iac etc.) were identified as a risk factor, 58% of patients have motor weakness and L4-L5 were the most frequent level
affected. Antibiotic therapy was used in accordance with current guidelines.
Conclusion: The clinical profile of our patients was 6 decades of life, male patients with neurological disabilities, clinical management has favorable results.
Scientific Research and Community Ltd
Title: Epidemiological Profile of Patients with Spondylodiscitis Treated at the Hospital Da Restauracao
Description:
Introduction: Spondylodiscitis is a global term that includes vertebral osteomyelitis, spondylitis and discitis, representing approximately 3 to 5% of all cases
of osteomyelitis.
It occurs in around 0.
5 to 2.
5 cases per 100,000 inhabitants/year, with men being more affected.
It has a bimodal peak incidence, the first peak
up to 20 years and the second between 50 and 70 years.
Most cases have an indication for non-surgical treatment, so surgery is reserved for specific cases.
Objective: To analyze the epidemiology of the population affected by spondylodiscitis and assess the response to surgical treatment.
Methods: We conducted a prospective cohort study in a tertiary center in Pernambuco, Recife, Brazil, investigating spondylodiscitis in all patients with back
pain without a history of trauma or neurological deficit without a diagnosis of degenerative spine disease.
The diagnosis of spondylodiscitis was confirmed
in all cases with magnetic resonance imaging.
The study period was two years.
Results: During the study period, we diagnosed 31 patients with spondylodiscitis, 58% were male, the mean age was 64.
9 years, the main comorbidities
were systemic arterial hypertension, dialysis renal failure and diabetes, previous non-neurological surgeries (Caesarean births, permanent vascular catheter
for dialysis, cardiac surgery on the iac etc.
) were identified as a risk factor, 58% of patients have motor weakness and L4-L5 were the most frequent level
affected.
Antibiotic therapy was used in accordance with current guidelines.
Conclusion: The clinical profile of our patients was 6 decades of life, male patients with neurological disabilities, clinical management has favorable results.
Related Results
Epidemiological and Clinical Profile of Tuberculous Spondylodiscitis: A Retrospective Study from Somalia
Epidemiological and Clinical Profile of Tuberculous Spondylodiscitis: A Retrospective Study from Somalia
Abstract
Background:
Spondylodiscitis remains a major cause of spinal morbidity in tuberculosis (TB)-endemic regions. This stud...
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Posterior Decompression and Fusion for Cervical Spondylodiscitis due to Osteoradionecrosis after Head-and-Neck Cancer Radiotherapy: Two Case Reports
Posterior Decompression and Fusion for Cervical Spondylodiscitis due to Osteoradionecrosis after Head-and-Neck Cancer Radiotherapy: Two Case Reports
Introduction: Cervical spondylodiscitis due to osteoradionecrosis (ORN) after head-and-neck cancer radiotherapy is a severe complication. However, there are few reports on the surg...
E039 Radiological features of brucellar spondylodiscitis
E039 Radiological features of brucellar spondylodiscitis
Abstract
Background/Aims
Osteoarticular involvement is the most common manifestation of focal brucellosis. Spinal involvement re...
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
1
Jose F.
Tellez‐Zenteno,
1
Scott B.
Patten, and
1
Samuel
Wiebe
...
The role of hyperbaric oxygen treatment in the management of spondylodiscitis
The role of hyperbaric oxygen treatment in the management of spondylodiscitis
Introduction: This study analysed treatment outcomes in a patient cohort diagnosed with spondylodiscitis, who received adjunct hyperbaric oxygen treatment (HBOT) in addition to ant...
Spontaneous spondylodiscitis: review, incidence, management, and clinical outcome in 44 patients
Spontaneous spondylodiscitis: review, incidence, management, and clinical outcome in 44 patients
OBJECTIVE
Spontaneous spondylodiscitis remains uncommon but is a serious complication of the vertebral column. Risk factors include diabetes, hemodialysis, intr...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

